Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the treatment of hospital-onset COVID-19

Document first published:
Page updated:
Publication type:

Neutralising monoclonal antibodies (nMABs) or antivirals are recommended to be available as a treatment option for COVID-19 through routine commissioning for adults and children (aged 12 years and above) in hospital with COVID-19 infection in accordance with the criteria set out in this document.


Rapid policy statement

Publication date: 30 May 2022
Effective from: 13 June 2022
Version: 7.0